Travere Therapeutics (TVTX) Shareholder's Equity Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.48% |
| Dec 31, 2025 | 38.90% |
| Sep 30, 2025 | -9.93% |
| Jun 30, 2025 | -40.66% |
| Mar 31, 2025 | -45.97% |
| Dec 31, 2024 | -41.96% |
| Sep 30, 2024 | -28.04% |
| Jun 30, 2024 | -64.28% |
| Mar 31, 2024 | -41.11% |
| Dec 31, 2023 | -1.67% |
| Sep 30, 2023 | -2.45% |
| Jun 30, 2023 | -28.50% |
| Mar 31, 2023 | -5.73% |
| Dec 31, 2022 | -42.14% |
| Sep 30, 2022 | -25.75% |
| Jun 30, 2022 | -17.30% |
| Mar 31, 2022 | -10.02% |
| Dec 31, 2021 | -1.72% |
| Sep 30, 2021 | -1.24% |
| Jun 30, 2021 | 4.89% |
| Mar 31, 2021 | 6.59% |
| Dec 31, 2020 | -10.35% |
| Sep 30, 2020 | -0.34% |
| Jun 30, 2020 | 2.51% |
| Mar 31, 2020 | -9.14% |
| Dec 31, 2019 | -10.43% |
| Sep 30, 2019 | -7.18% |
| Jun 30, 2019 | -4.12% |
| Mar 31, 2019 | -3.63% |
| Dec 31, 2018 | 1.99% |
| Sep 30, 2018 | 3.12% |
| Jun 30, 2018 | 24.07% |
| Mar 31, 2018 | 21.11% |
| Dec 31, 2017 | 114.50% |
| Sep 30, 2017 | 217.12% |
| Dec 31, 2016 | 160.36% |
| Sep 30, 2016 | 224.32% |
| Mar 31, 2016 | 365.84% |